The TACTICS trial for TACE plus sorafenib reported significant adverse effects, including elevated ALT/AST levels (23.4% and 22.1%, respectively), thrombocytopenia (13.0%), and hypertension (10.4%) [126,127]. The gene discussed is GPT; the disease is hypertensive disorder.